Big Pharma On The Run To Lose $15,5 Billion If All 50 States Legalize Medical Marijuana

Being one of the key influencers in the US economy, Pharmaceutical companies like Big Pharma have turned their back on medical and recreational marijuana legalization as they will be left with a bank deficit of $18,5 Billion.

In the legal medical states the usage of essential prescription drugs is already down by 11 %. The National Academies of Science have shown their interest to closely monitor the cases where different conditions have been effectively treated with medical marijuana concluding that each condition has a substitute of high-profit pharmaceuticals.

Chronic pain, post-traumatic stress disorder, sleep disorders, anxiety, nerve pain, chemotherapy-induced nausea and vomiting (CINV), Tourette syndrome, glaucoma, and seizures/epilepsy are the most common conditions effectively treated by medical cannabis.

Big Pharma represents a powerful and successful pharmaceutical industry and counting the loss of $18,5 Billion over a three-year period would leave the company vulnerable, “medical cannabis would be a drop in the bucket when it comes to impacting the total pharmaceutical industry”, as Giadha Aguirre De Carcer, founder and CEO of New Frontier Data stated.